Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06203002
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-11
First Post:
2023-11-30
Brief Title:
A Dose-ranging Study in Patients with Diabetic Peripheral Neuropathic Pain DPNP
Sponsor:
Lexicon Pharmaceuticals
Organization:
Lexicon Pharmaceuticals
Study Overview
Official Title:
A Phase 2b Dose-ranging Randomized Double-blind PlacebO-controlled Parallel-GRoup MulticEnter Study in PatientS with Diabetic Peripheral Neuropathic Pain PROGRESS
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROGRESS
Brief Summary:
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP Please see study website httpsdiabeticpainstudycom
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LX9211204-DPN | OTHER | Lexicon Pharmaceuticals Inc | None |